Track topics on Twitter Track topics that are important to you
DelveInsight's Narcolepsy Market Insights, Epidemiology and Market Forecast2023 Report provides an overview of the disease and global market size of the Narcolepsy for the 7MM United States, EU5 France, Germany, Italy, Spain and UK and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Narcolepsy from 20132023.
Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations.
Narcolepsy affects approximately 200,000 Americans and 3 million people worldwide. Narcolepsy is not rare, but it is severely underrecognized and commonly misdiagnosed. Narcolepsy appears throughout the world but occurrence rates vary among populations. The occurrence rate of narcolepsy is remarkably lower in Israel and quite higher in Japan compared to the United States. In Europe, the occurrence rate is found to be higher in UK and Germany than other European countries.
PROVIGIL by Cephalon, Inc and XYREM by Jazz Pharmaceuticals is the top selling drug for Narcolepsy contributing to majority of the market share. Other drugs are also being used for the treatment of Narcolepsy as secondary indication, but do not have much impact on the overall market size. We have estimated that the worldwide Narcolepsy will increase at a CAGR of 8.48% during the forecast period 20132023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse Forecast model analysis by Publisher team of industry experts.
Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 20132023.
It also provides Market size of Narcolepsy for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Narcolepsy Market 7MM
Narcolepsy Sales forecasting
Narcolepsy Market segments
Narcolepsy Pipeline products and technologies
Narcolepsy Competitive landscape
Narcolepsy SWOT analysis
Narcolepsy Market Driver's and barriers
Narcolepsy Key Companies and Funding
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...